Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: Lessons and pitfalls in a real-world setting.

Ureña-Paniego, C; Haselgruber, S; Soto-Moreno, A; Cuenca-Barrales, C; Arias-Santiago, S; Molina-Leyva, A

Ureña-Paniego, C; Haselgruber, S; Soto-Moreno, A; Cuenca-Barrales, C; Arias-Santiago, S; Molina-Leyva, A.

Affiliation

Ureña-Paniego C; Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Haselgruber S; Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Soto-Moreno A; Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Cuenca-Barrales C; Dermatology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Arias-Santiago S; Hidradenitis Suppurativa Clinic, Hospital Universitario Virgen de las Nieves, Granada, Spain.
Molina-Leyva A; Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain.

J Eur Acad Dermatol Venereol ; 38(9): e823-e824, 2024 Sep.

Article in En | MEDLINE | ID: mdl-38411288

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hidradenitis Suppurativa Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2024 Document type: Article Affiliation country: España Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google